13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
33 檔
33.1%
According to the latest 13F quarterly dataset, Commodore Capital LP managed an equity portfolio of $1.7B at the end of Q2 2025, spanning 33 distinct U.S. exchange-listed positions.
In Q2 2025, Commodore Capital LP displayed an active expansion posture, initiating 7 new positions and adding to 10 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 13.09% | — | -21.19% | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 7.41% | -4.20% | -25.88% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 6.68% | -2.78% | EXIT | |
| 4 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.64% | +2.47% | +0.38% | |
| 5 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 5.46% | — | +6.41% | |
| 6 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.96% | -1.96% | +7.81% | |
| 7 | ALKS | Alkermes plc | Stock-Healthcare | 4.95% | +0.77% | +25.64% | |
| 8 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.81% | — | +35.42% | |
| 9 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.19% | — | — | |
| 10 | CDTX | Cidara Therapeutics Inc | Stock-Other | 4.04% | — | — | |
| 11 | SRRK | Scholar Rock Holding CORP | Stock-Other | 3.63% | — | -16.91% | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.61% | -1.26% | EXIT | |
| 13 | RLAY | Relay Therapeutics Inc | Stock-Other | 3.26% | +3.58% | — | |
| 14 | NRIX | Nurix Therapeutics Inc | Stock-Other | 3.17% | -2.04% | EXIT | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.06% | — | +39.31% | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 2.37% | -0.21% | — | |
| 17 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.31% | -1.90% | — | |
| 18 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.29% | — | +10.50% | |
| 19 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.10% | -1.10% | — | |
| 20 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.09% | -1.91% | +226.32% | |
| 21 | VERA | Vera Therapeutics Inc | Stock-Other | 1.33% | — | -68.77% | |
| 22 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.23% | — | — | |
| 23 | COGT | Cogent Biosciences Inc | Stock-Other | 1.17% | +0.60% | -74.01% | |
| 24 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.12% | — | — | |
| 25 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.92% | — | — | |
| 26 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 27 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.74% | +0.13% | +0.99% | |
| 28 | ✓ | Stock-Other | 0.56% | — | — | ||
| 29 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.54% | +4.19% | NEW | |
| 30 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.52% | — | — | |
| 31 | NGNE | Neurogene Inc | Stock-Other | 0.45% | — | -53.74% | |
| 32 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.22% | +0.04% | NEW | |
| 33 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.17% | +0.70% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | +4.2% | NEW | New buy |
| 2 | CDTX | Cidara Therapeutics Inc | +4% | NEW | New buy |
| 3 | RLAY | Relay Therapeutics Inc | +3.3% | NEW | New buy |
| 4 | KYMR | Kymera Therapeutics Inc | +2.3% | NEW | New buy |
| 5 | TYRA | Tyra Biosciences Inc | +1.4% | +226.32% | Add |
| 6 | VRDN | Viridian Therapeutics Inc | +1.2% | +35.42% | Add |
| 7 | CTMX | Cytomx Therapeutics Inc | +1.2% | NEW | New buy |
| 8 | XENE | Xenon Pharmaceuticals Inc | +0.9% | +30.11% | Add |
| 9 | AGIO | Agios Pharmaceuticals Inc | +0.7% | +6.41% | Add |
| 10 | CLDX | Celldex Therapeutics Inc | +0.7% | +7.81% | Add |
| 11 | 260 | Centessa Pharmaceuticals-adr | +0.6% | +39.31% | Add |
| 12 | TNGX | Tango Therapeutics Inc | +0.5% | NEW | New buy |
| 13 | ✓ | Crescent Biopharma Inc. | +0.5% | NEW | New buy |
| 14 | BRD1EUR | Mind Medicine Mindmed Inc | +0.3% | +10.50% | Add |
| 15 | ALKS | Alkermes plc | +0.2% | +25.64% | Add |
| 16 | PHVS | Pharvaris N.V. | +0.2% | — | Unchanged |
| 17 | APGE | Apogee Therapeutics Inc | +0.1% | — | Unchanged |
| 18 | ORKA | Oruka Therapeutics Inc | +0.1% | — | Unchanged |
| 19 | ✓ | 0% | — | Unchanged | |
| 20 | VTGN | Vistagen Therapeutics Inc | -0.1% | — | Unchanged |
| 21 | AVTX | Avalo Therapeutics Inc | -0.1% | — | Unchanged |
| 22 | IKT | Inhibikase Therapeutics Inc | -0.1% | +0.99% | Add |
| 23 | ELVN | Enliven Therapeutics Inc | -0.1% | +0.38% | Add |
| 24 | SYRE | Spyre Therapeutics Inc | -0.3% | — | Unchanged |
| 25 | NRIX | Nurix Therapeutics Inc | -0.3% | -0.76% | Trim |
| 26 | NGNE | Neurogene Inc | -0.4% | -53.74% | Trim |
| 27 | DRUG | Bright Minds Biosciences Inc | -0.4% | — | Unchanged |
| 28 | SRRK | Scholar Rock Holding CORP | -0.5% | -16.91% | Trim |
| 29 | CELC | Celcuity Inc | -0.5% | EXIT | Sold out |
| 30 | ✓ | Merus N V | -0.8% | -21.19% | Trim |
| 31 | ORIC | Oric Pharmaceuticals Inc | -0.8% | EXIT | Sold out |
| 32 | CRDF | Cardiff Oncology Inc | -1.3% | EXIT | Sold out |
| 33 | SLDB | Solid Biosciences Inc | -1.6% | EXIT | Sold out |
| 34 | NUVL | Nuvalent Inc-a | -2.3% | -25.88% | Trim |
| 35 | SLNOEUR | Soleno Therapeutics Inc | -2.4% | -46.96% | Trim |
| 36 | COGT | Cogent Biosciences Inc | -2.8% | -74.01% | Trim |
| 37 | VERA | Vera Therapeutics Inc | -3.2% | -68.77% | Trim |
| 38 | PCVX | Vaxcyte Inc | -4.6% | EXIT | Sold out |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 33 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, NUVL, XENE) accounted for 33.1% of total reported equity market value during Q2 2025.
Top New Position Initiated
PTGX
市值: $59.4M
Top Position Liquidated / Trimmed
PCVX
前期市值: $62.3M
During Q2 2025, Commodore Capital LP's top holdings by market value included MERUS N V (13.1%)、NUVL (7.4%)、XENE (6.7%). The largest single position, MERUS N V, represented 13.1% of total portfolio value.
In Q2 2025, Commodore Capital LP made 30 total portfolio adjustments, initiating 7 new buys, adding to 10 positions, trimming 8 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.